Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics has demonstrated a robust market presence, evidenced by the meaningful increase in Chromium reaction volumes, suggesting continued demand amidst challenges in the pharmaceutical sector. The company's consumables are projected to grow significantly, with estimates indicating a 5-19x increase by 2027, outpacing instrument revenue growth. This momentum in consumables aligns well with the company's integrated solutions for analyzing biological systems, providing a strong foundation for future financial performance.

Bears say

10x Genomics experienced a contraction in 2024, marked by double-digit pricing pressure that negatively impacted revenues, alongside flat to modestly lower volumes, with growth not anticipated to resume until 2027. The company reported weaker than expected fourth-quarter results, including an earnings per share miss and a full-year revenue outlook that fell short of market expectations. Since reaching peak stock prices in 2021, 10x Genomics has seen its stock decline by over 90%, as its market segments have not expanded to the levels anticipated by analysts.

10X Genomics (TXG) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 13 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Jan 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.